AUSTIN, June 24, 2014 -- On June 23, 2014, ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced the closing of its initial public offering of 6,836,111 shares of common stock at a public offering price of $18.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 891,667 additional shares of common stock. The net proceeds from the sale of shares, after deducting underwriting discounts, commissions and other estimated offering expenses, will be approximately $112 million.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. BMO Capital Markets Corp. acted as lead manager and William Blair & Company, L.L.C. acted as co-manager.
Baker Botts represented ZS Pharma in its IPO and has represented the company since its Series B financing in 2010.
# # #
About Baker Botts L.L.P.
Baker Botts is an international law firm of approximately 700 lawyers practicing throughout a network of 15 offices around the globe. Based on our experience and knowledge of our clients’ industries, we are recognized as a leading firm in the energy, technology and life sciences sectors. Throughout our 174-year history, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit BakerBotts.com.